OCULAR THERAPEUTIX, INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
OCULAR THERAPEUTIX, INC (OCUL) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 1.48 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2026-08-03
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-06-30 was 1.48M shares, a 683.04% increase year-over-year.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2026-03-31 was 419.68K shares, a 59.98% decline year-over-year.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-12-31 was 173.89K shares, a 65.77% decline year-over-year.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2025-09-30 was 262.43K shares, a 67.00% decline year-over-year.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2025 was 1.67M shares, a 28.55% decline from fiscal 2024.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2024 was 2.34M shares, a 151.06% increase from fiscal 2023.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 933.46K shares, a 2.93% decline from fiscal 2022.
- OCULAR THERAPEUTIX, INC share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 961.67K shares, a 4.42% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.48M shares 10-Q · filed 2026-08-03 | 1.90M shares 10-Q · filed 2026-08-03 | 2.08M shares derived: sum of 3 quarters · filed 2026-08-03 | 2.34M shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 419.68K shares 10-Q · filed 2026-05-05 | 593.56K shares derived: sum of 2 quarters · filed 2026-05-05 | 855.99K shares derived: sum of 3 quarters · filed 2026-05-05 | 1.05M shares derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | 173.89K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-05 | 436.32K shares derived: sum of 2 quarters · filed 2026-02-05 | 625.77K shares derived: sum of 3 quarters · filed 2026-02-05 | 1.67M shares 10-K · filed 2026-02-05 |
| 2025-09-30 | 262.43K shares 10-Q · filed 2025-11-04 | 451.88K shares derived: sum of 2 quarters · filed 2025-11-04 | 1.50M shares 10-Q · filed 2025-11-04 | 2.01M shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 189.46K shares 10-Q · filed 2025-08-05 | 1.24M shares 10-Q · filed 2025-08-05 | 1.75M shares derived: sum of 3 quarters · filed 2025-08-05 | 2.54M shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 1.05M shares 10-Q · filed 2025-05-05 | 1.56M shares derived: sum of 2 quarters · filed 2025-05-05 | 2.35M shares derived: sum of 3 quarters · filed 2025-05-05 | 3.08M shares derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | 508.02K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | 1.30M shares derived: sum of 2 quarters · filed 2025-03-03 | 2.03M shares derived: sum of 3 quarters · filed 2025-03-03 | 2.34M shares 10-K · filed 2025-03-03 |
| 2024-09-30 | 795.23K shares 10-Q · filed 2024-11-14 | 1.53M shares derived: sum of 2 quarters · filed 2024-11-14 | 1.84M shares 10-Q · filed 2024-11-14 | |
| 2024-06-30 | 731.58K shares 10-Q · filed 2024-08-07 | 1.04M shares 10-Q · filed 2024-08-07 | ||
| 2024-03-31 | 308.68K shares derived: 10-K 12 month − 3 quarters · filed 2025-03-03 | |||
| 2023-12-31 | 933.46K shares 10-K · filed 2024-03-11 | |||
| 2022-12-31 | 961.67K shares 10-K · filed 2023-03-06 | |||
| 2021-12-31 | 920.96K shares 10-K · filed 2022-02-28 | |||
| 2020-12-31 | 687.86K shares 10-K · filed 2021-03-11 | |||
| 2019-12-31 | 1.27M shares 10-K · filed 2020-03-12 | |||
| 2018-12-31 | 472.44K shares 10-K · filed 2019-03-07 | |||
| 2017-12-31 | 1.22M shares 10-K · filed 2018-03-08 | |||
| 2016-12-31 | 65.95K shares 10-K · filed 2017-03-10 | |||
| 2015-12-31 | 34.85K shares 10-K · filed 2016-03-10 | |||
| 2014-12-31 | 21.93K shares 10-K · filed 2015-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |